Currently, PI3K and mTOR inhibitors are already approved in advanced breast cancer, while recently, AKT inhibitors have been recently developed as an innovative therapeutic approach (Andrikopoulou et al., 2022a). This evidence concerns the gene AKT1 and breast carcinoma.